986P Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy c... von Chon, H., Heo, J., Evans, T.R.J., Kim, D.Y., Lim, H.Y., Macarulla Mercade, T., Gomez Martin, C., Moreno Garcia, V., Ryu, M.H., Baumann, P., Bhoi, S., Jensen, M., Tunblad, K., Wallberg, H., Öberg, F.G., Reig Monzon, M.E.

Volltext

176P Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma von Chon, H.J., Heo, J., Monzon, M.E. Reig, Mercade, T. Macarulla, Garcia, V. Moreno, Haugk, B., Ness, T., Bhoi, S., Jensen, M., Tunblad, K., Wallberg, H., Baumann, P., Öberg, F.G.

Volltext

167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) von Monzon, M.E. Reig, Tam, V.C., Sangro, B., Archambeaud, I., Kelley, R.K., Chan, S.L., Kudo, M., Masi, G., Paskow, M.J., Makowsky, M., Gupta, C., Ran, D., Negro, A., Abou-Alfa, G.K.

Volltext

979P Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Ph... von Reig Monzon, M.E., Luque Caro, N., Bruix, J., Gomez Martin, C., Sangro, B., Sastre Varela, J., Ordoñez Tres, J.M., Argemi, J., Perez Lopez, R., Torres Candela, M.P., Lledó-Navarro, J.L., Matilla Peña, A.M., Montero, J-L., Pazo Cid, R.A., Varela, M.

Volltext

79P Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study von Vogel, A., Chan, S.L., Furuse, J., Tak, W.Y., Masi, G., Varela, M., Kim, J.H., Tanasanvimon, S., Reig Monzon, M.E., Dayyani, F., Makowsky, M., Marcovitz, M., Negro, A., Abou-Alfa, G.K.

Volltext

147P Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) von Chan, S.L., Sangro, B., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., De Toni, E.N., Furuse, J., Kang, Y-K., Galle, P.R., Rimassa, L., Heurgue, A., Tam, V.C., Dao, T.V., Chiradoni Thungappa, S., Breder, V., Ostapenko, Y.V., Reig Monzon, M.E., Gupta, C., Abou-Alfa, G.K.

Volltext

83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) von Chan, S.L., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Ran, D., Negro, A., Abou-Alfa, G.K.

Volltext

67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) von Chan, S.L., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Gupta, C., Negro, A., Abou-Alfa, G.K.

Volltext

714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) von Chan, L.S., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Ran, D., Negro, A., Abou-Alfa, G.K.

Volltext